Salmeterol Xinafoate

API Product
salmeterol-xinafoate
Product Status:
Commercial
Available Grades:
  • Inhalation
Regulatory Status:
US DMF
CEP
Production Sites:
  • Hovione Loures
Product Type:
  • LABA
  • LAMA
CAS Number:
94749-08-3
Modes of Application:
  • Inhalation
Common Indications:
  • Asthma
  • COPD
Last Inspection:
FDA May 2018

Hovione can customize Salmeterol Xinafoate for inhalation with an unrivalled range of particle size reduction technologies for the production of tailor made API, featuring a near-perfect particle size distribution reproducibility with a low span and amorphous content, providing highly stable API.

Hovione Salmeterol Xinafoate is approved in generic applications.

With a proven track record in developing and manufacturing high performance APIs Hovione offers a full range of API for inhalation, e.g. Fluticasone Propionate.

 

 

 


This is not to be construed as a representation of non-infringement or as an offer to sell in those countries where such would constitute an infringement of third parties' patent rights.

Highlight

Contact Us

Please contact us if you have inquiries about our offering

https://go.hovione.com/l/47122/2014-08-06/9grc

Related files

Hovione - Integrated Product List.pdf
pdf (3.28 MB)
Download

Related Content

Dry Powder Inhalation formulation development

Hovione has considerable inhalation experience that allows us to implement strategies including conventional carrier based, neat (drug-alone) or composite particle formulations.

Page
Read more

Drug Product Manufacturing

To extend Hovione further we are now able to offer clinical supplies manufacturing for drug products.

Page
Read more

Jet milling

Jet milling is widely used in the pharmaceutical industry and remains the leading technology for particle size reduction and is most commonly used for having consistent and uniform particles during formulation.

Page
Read more